vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Verisign (VRSN). Click either name above to swap in a different company.
Verisign is the larger business by last-quarter revenue ($425.3M vs $281.3M, roughly 1.5× Guardant Health, Inc.). Verisign runs the higher net margin — 48.5% vs -45.7%, a 94.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 7.6%). Verisign produced more free cash flow last quarter ($285.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.
GH vs VRSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $425.3M |
| Net Profit | $-128.5M | $206.2M |
| Gross Margin | 64.6% | 88.5% |
| Operating Margin | -43.0% | 67.0% |
| Net Margin | -45.7% | 48.5% |
| Revenue YoY | 39.4% | 7.6% |
| Net Profit YoY | -15.8% | 7.7% |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $425.3M | ||
| Q3 25 | $265.2M | $419.1M | ||
| Q2 25 | $232.1M | $409.9M | ||
| Q1 25 | $203.5M | $402.3M | ||
| Q4 24 | $201.8M | $395.4M | ||
| Q3 24 | $191.5M | $390.6M | ||
| Q2 24 | $177.2M | $387.1M | ||
| Q1 24 | $168.5M | $384.3M |
| Q4 25 | $-128.5M | $206.2M | ||
| Q3 25 | $-92.7M | $212.8M | ||
| Q2 25 | $-99.9M | $207.4M | ||
| Q1 25 | $-95.2M | $199.3M | ||
| Q4 24 | $-111.0M | $191.5M | ||
| Q3 24 | $-107.8M | $201.3M | ||
| Q2 24 | $-102.6M | $198.8M | ||
| Q1 24 | $-115.0M | $194.1M |
| Q4 25 | 64.6% | 88.5% | ||
| Q3 25 | 64.7% | 88.4% | ||
| Q2 25 | 65.0% | 88.0% | ||
| Q1 25 | 63.3% | 87.7% | ||
| Q4 24 | 61.6% | 87.8% | ||
| Q3 24 | 61.1% | 88.0% | ||
| Q2 24 | 59.1% | 87.8% | ||
| Q1 24 | 61.2% | 87.2% |
| Q4 25 | -43.0% | 67.0% | ||
| Q3 25 | -37.3% | 67.8% | ||
| Q2 25 | -45.9% | 68.5% | ||
| Q1 25 | -54.6% | 67.4% | ||
| Q4 24 | -62.4% | 66.7% | ||
| Q3 24 | -61.3% | 68.9% | ||
| Q2 24 | -56.8% | 68.8% | ||
| Q1 24 | -59.2% | 67.4% |
| Q4 25 | -45.7% | 48.5% | ||
| Q3 25 | -35.0% | 50.8% | ||
| Q2 25 | -43.0% | 50.6% | ||
| Q1 25 | -46.8% | 49.5% | ||
| Q4 24 | -55.0% | 48.4% | ||
| Q3 24 | -56.3% | 51.5% | ||
| Q2 24 | -57.9% | 51.4% | ||
| Q1 24 | -68.2% | 50.5% |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | — | ||
| Q2 25 | $-0.80 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | — | ||
| Q2 24 | $-0.84 | — | ||
| Q1 24 | $-0.94 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $580.5M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $-2.2B |
| Total Assets | $2.0B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $580.5M | ||
| Q3 25 | $580.0M | $617.7M | ||
| Q2 25 | $629.1M | $593.8M | ||
| Q1 25 | $698.6M | $648.5M | ||
| Q4 24 | $525.5M | $599.9M | ||
| Q3 24 | $585.0M | $644.9M | ||
| Q2 24 | $933.7M | $689.9M | ||
| Q1 24 | $1.0B | $924.7M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-2.2B | ||
| Q3 25 | $-354.5M | $-2.1B | ||
| Q2 25 | $-305.5M | $-2.0B | ||
| Q1 25 | $-250.8M | $-2.0B | ||
| Q4 24 | $-139.6M | $-2.0B | ||
| Q3 24 | $-60.1M | $-1.9B | ||
| Q2 24 | $-1.6M | $-1.8B | ||
| Q1 24 | $68.3M | $-1.6B |
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.5B | $1.4B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.7B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $289.6M |
| Free Cash FlowOCF − Capex | $-54.2M | $285.1M |
| FCF MarginFCF / Revenue | -19.3% | 67.0% |
| Capex IntensityCapex / Revenue | 9.9% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $289.6M | ||
| Q3 25 | $-35.4M | $307.7M | ||
| Q2 25 | $-60.3M | $202.5M | ||
| Q1 25 | $-62.7M | $291.3M | ||
| Q4 24 | $-64.5M | $231.5M | ||
| Q3 24 | $-51.1M | $253.4M | ||
| Q2 24 | $-94.0M | $160.4M | ||
| Q1 24 | $-30.3M | $257.3M |
| Q4 25 | $-54.2M | $285.1M | ||
| Q3 25 | $-45.8M | $303.0M | ||
| Q2 25 | $-65.9M | $194.7M | ||
| Q1 25 | $-67.1M | $285.5M | ||
| Q4 24 | $-83.4M | $222.0M | ||
| Q3 24 | $-55.3M | $247.8M | ||
| Q2 24 | $-99.1M | $151.2M | ||
| Q1 24 | $-37.2M | $253.5M |
| Q4 25 | -19.3% | 67.0% | ||
| Q3 25 | -17.3% | 72.3% | ||
| Q2 25 | -28.4% | 47.5% | ||
| Q1 25 | -33.0% | 71.0% | ||
| Q4 24 | -41.3% | 56.1% | ||
| Q3 24 | -28.9% | 63.4% | ||
| Q2 24 | -55.9% | 39.1% | ||
| Q1 24 | -22.1% | 66.0% |
| Q4 25 | 9.9% | 1.1% | ||
| Q3 25 | 3.9% | 1.1% | ||
| Q2 25 | 2.4% | 1.9% | ||
| Q1 25 | 2.2% | 1.4% | ||
| Q4 24 | 9.4% | 2.4% | ||
| Q3 24 | 2.2% | 1.4% | ||
| Q2 24 | 2.9% | 2.4% | ||
| Q1 24 | 4.1% | 1.0% |
| Q4 25 | — | 1.40× | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | — | 1.21× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 1.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
VRSN
Segment breakdown not available.
